Gilead Sciences, Inc. (GILD) Holdings Trimmed by E&G Advisors LP

E&G Advisors LP trimmed its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 4.7% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 26,097 shares of the biopharmaceutical company’s stock after selling 1,298 shares during the quarter. Gilead Sciences makes up approximately 0.8% of E&G Advisors LP’s holdings, making the stock its 24th biggest position. E&G Advisors LP’s holdings in Gilead Sciences were worth $1,870,000 as of its most recent SEC filing.

A number of other hedge funds have also bought and sold shares of GILD. Bank of Montreal Can raised its holdings in shares of Gilead Sciences by 23.1% during the 4th quarter. Bank of Montreal Can now owns 2,559,990 shares of the biopharmaceutical company’s stock worth $183,397,000 after acquiring an additional 479,620 shares in the last quarter. CWM LLC raised its holdings in shares of Gilead Sciences by 2.5% during the 4th quarter. CWM LLC now owns 83,213 shares of the biopharmaceutical company’s stock worth $5,961,000 after acquiring an additional 2,009 shares in the last quarter. Greylin Investment Mangement Inc. raised its holdings in shares of Gilead Sciences by 89.5% during the 4th quarter. Greylin Investment Mangement Inc. now owns 48,837 shares of the biopharmaceutical company’s stock worth $3,499,000 after acquiring an additional 23,060 shares in the last quarter. BLB&B Advisors LLC raised its holdings in shares of Gilead Sciences by 32.6% during the 4th quarter. BLB&B Advisors LLC now owns 5,060 shares of the biopharmaceutical company’s stock worth $362,000 after acquiring an additional 1,245 shares in the last quarter. Finally, Atria Investments LLC raised its holdings in shares of Gilead Sciences by 305.1% during the 4th quarter. Atria Investments LLC now owns 69,230 shares of the biopharmaceutical company’s stock worth $4,960,000 after acquiring an additional 52,140 shares in the last quarter. Institutional investors and hedge funds own 75.71% of the company’s stock.

In other news, Director Gayle E. Wilson sold 60,000 shares of the stock in a transaction on Friday, February 9th. The stock was sold at an average price of $77.92, for a total transaction of $4,675,200.00. Following the transaction, the director now owns 182,258 shares of the company’s stock, valued at approximately $14,201,543.36. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider John C. Martin sold 73,333 shares of the stock in a transaction on Friday, December 1st. The stock was sold at an average price of $74.98, for a total value of $5,498,508.34. Following the transaction, the insider now directly owns 3,070,099 shares in the company, valued at approximately $230,196,023.02. The disclosure for this sale can be found here. In the last quarter, insiders sold 418,333 shares of company stock worth $32,742,108. Insiders own 1.30% of the company’s stock.

Shares of Gilead Sciences, Inc. (NASDAQ:GILD) opened at $80.70 on Monday. The company has a debt-to-equity ratio of 1.10, a current ratio of 3.55 and a quick ratio of 3.48. Gilead Sciences, Inc. has a 52 week low of $63.76 and a 52 week high of $89.54. The firm has a market capitalization of $105,415.91, a price-to-earnings ratio of 9.45, a price-to-earnings-growth ratio of -1.85 and a beta of 1.22.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.78 earnings per share for the quarter, topping analysts’ consensus estimates of $1.67 by $0.11. Gilead Sciences had a return on equity of 50.29% and a net margin of 17.73%. The business had revenue of $5.95 billion for the quarter, compared to analyst estimates of $5.71 billion. During the same quarter last year, the firm posted $2.70 earnings per share. The business’s revenue was down 18.7% compared to the same quarter last year. sell-side analysts expect that Gilead Sciences, Inc. will post 6.24 EPS for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, March 29th. Shareholders of record on Friday, March 16th will be paid a $0.57 dividend. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.52. The ex-dividend date of this dividend is Thursday, March 15th. This represents a $2.28 dividend on an annualized basis and a yield of 2.83%. Gilead Sciences’s dividend payout ratio (DPR) is presently 59.77%.

Several analysts have recently issued reports on the company. ValuEngine raised Gilead Sciences from a “buy” rating to a “strong-buy” rating in a report on Thursday, February 8th. Credit Suisse Group set a $80.00 price objective on Gilead Sciences and gave the stock a “hold” rating in a report on Wednesday, January 3rd. Leerink Swann decreased their price objective on Gilead Sciences from $86.00 to $83.00 and set a “market perform” rating on the stock in a report on Wednesday, February 7th. Mizuho increased their price target on Gilead Sciences from $77.00 to $83.00 and gave the company a “buy” rating in a report on Wednesday, November 8th. Finally, BMO Capital Markets decreased their price target on Gilead Sciences from $89.00 to $83.00 and set an “outperform” rating on the stock in a report on Friday, October 27th. One equities research analyst has rated the stock with a sell rating, twelve have given a hold rating, seventeen have issued a buy rating and two have given a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $87.04.

ILLEGAL ACTIVITY NOTICE: This piece was originally posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this piece on another publication, it was copied illegally and republished in violation of US & international copyright and trademark laws. The legal version of this piece can be read at https://ledgergazette.com/2018/02/19/gilead-sciences-inc-gild-holdings-trimmed-by-eg-advisors-lp.html.

Gilead Sciences Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply